Chiesi Industry Innovators - Patient first: innovation in environmentally responsible inhaled therapy with Prof Dave Singh
| Monday, March 25, 2024 |
| 12:35 PM - 12:55 PM |
| Theatrette 2 |
Details
Patient first. This principle lies at the heart of modern medicine. To ensure clinicians’ ability to provide this, innovations in new carbon minimal formulations of pressurised metered dose inhalers (pMDI) for asthma and COPD are well underway.
F-gases are a minor but potent greenhouse gas used in refrigeration and as propellants in currently available pMDIs. Learn about developments of a new generation of propellants, the implications for inhaled therapies in a carbon constrained future and balancing care for patients and the environment.
Because the best inhaler is the one a patient can and will use.
Speaker
Prof Dave Singh
Professor of Clinical Pharmacology and Respiratory Medicine
University of Manchester
Patient first: innovation in environmentally responsible inhaled therapy
12:35 PM - 12:55 PMBiography
Internationally renowned respiratory expert, Professor of Clinical Pharmacology and Respiratory Medicine at the University of Manchester, UK. He is also a European Respiratory Society (ERS) Gold medal winner for his outstanding contribution to COPD. His research interest is the development of new drugs for asthma and COPD. He has acted as principal investigator in over 400 clinical trials and has over 400 publications. He is a member of the Global Initiative for Chronic Obstructive Lung Disease Science Committee and was previously the chair of the ERS airway pharmacology group. He is currently an editor of the European Respiratory Journal and European Respiratory Review. He is a fellow of the European Respiratory Society and of the British Pharmacology Society.
